Kornimate/medical-research-clean huggingface dataset:
daily assessment of mood and social media behaviors study

Conditions: Anxiety; Stress; Depression; Cortisol

Summary: the purpose of this research study is to learn more about social media usage and its relation to emotions, biology, and mental health. participants will complete daily assessments (5 times a day) over the course of 11 days in which they will report on their social media use, behaviors, and mood. during the first 4 days participants will be asked to continue using social media as typical. in the second half (7 days) participants will be randomized to social media usage groups (0 minutes, 30 minutes, 1 hour, 2 hour, 3 hours). there will be mental health and well-being measures provided at the beginning and end of the study. lastly, to better understand how social media usage effects underlying mechanisms of stress, participants will be asked to provide saliva samples for 3 nights (pre, mid, and post) to assess for basal cortisol levels.


Eligibility criteria:
inclusion criteria: * having a smartphone exclusion criteria: * below age of 18

Keywords: social media
collecting and storing biological samples from young patients with hodgkin?s lymphoma

Conditions: Ann Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Ann Arbor Stage III Childhood Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Hodgkin Lymphoma; Refractory Childhood Hodgkin Lymphoma

Summary: this laboratory study is collecting and storing samples of tissue and blood from young patients with hodgkin's lymphoma. collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help the study of cancer in the future.

objectives: i. establish a biologic specimen repository (of tumor tissue, tissue arrays, lymphoblastoid cell lines, host dna, tumor and host rna, serum, and plasma) and database linked to clinical features and outcomes from well-characterized cohorts of children and young adults with hodgkin's lymphoma. ii. provide specimens from diagnosis, early response evaluation, completion of chemotherapy and radiotherapy, long-term follow up, and relapse to study prognostic factors for early response, relapse, long-term outcomes, and identification of new biological targets for therapy. outline: this is a multicenter study. patients enrolled on hodgkin's lymphoma (hl) therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression. patients with relapsed or progressive disease who plan to enroll on hl relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression. patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation.

Eligibility criteria:
inclusion criteria: * histologically confirmed hodgkin's lymphoma (hl) meeting 1 of the following criteria: * newly diagnosed, untreated hl (for patients under 22 years of age) * past or present diagnosis of hl and past or present enrollment on a children's oncology group (cog) or legacy hl clinical trial (for patients of any age)
interest of bone scintigraphy in the search for scaphotrapezoidal osteoarthritis

Conditions: Rhizarthrosis; Prosthesis Failure

Summary: rhizarthosis can be treated by prothesis of the carpo-metacarpal (cm) joint of the thumb. but, if the scaphotrapeziotrapezoid (stt) joint is also affected by arthrosis, treating the cm joint exclusively may result in partial pain relief. thus, bone scintigraphy could identify early arthrosis of the stt joint when its appearance seems to be normal on planar radiography, suggesting another surgical procedure.


Eligibility criteria:
inclusion criteria: * failure of medical treatment of rhizarthrosis * eligibility for prothesis * no osteoarthritis of the stt joint on planar radiography * no opposition from the patient exclusion criteria: * refusal by a patient

Keywords: rhizarthrosis bone scintigraphy
study of the safety, tolerability, pharmacokinetics and pharmacodynamics of acu-4429 in subjects with geographic atrophy

Conditions: Dry Age-related Macular Degeneration; Geographic Atrophy

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug acu-4429 in subjects with geographic atrophy.


Eligibility criteria:
inclusion criteria: * have a clinical diagnosis of geographic atrophy, as defined in the protocol exclusion criteria: * currently receiving or has received a medication prohibited by the protocol
the efficacy of continuous femoral nerve catheter orifice configuration for postoperative analgesia in knee arthroplasty

Conditions: Anesthesia; Catheter Blockage; Knee Arthropathy; Pain, Postoperative

Summary: femoral nerve catheter for postoperative analgesia will be included in the adult patients undergoing total knee arthroplasty included in the study. these patients will be randomized to the catheter tip configuration as cemp (closed-ended multiport catheter) group and oesp (open-ended single port catheter) group. patient controlled analgesia device will be attached to the peripheral nerve catheter of these patients. demographic data of the patients , the number of pushing the button the amount of bolus dose given, and the total dose given in the patient controlled anesthesia device, the need for additional analgesia and the amount, pain scores, complications will be recorded for three days postoperatively. records will be compared statistically.

ethics committee approval was received on 10 december 2019, numbered 19/397. the study was planned to include 90 adult patients undergoing total knee arthroplasty at gülhane training and research hospital between 10 december 2019 and april 2020. continue femoral nerve catheter for postoperative analgesia will be included in the patients included in the study. these patients will be randomized to the catheter tip configuration as cemp (closed-ended multiport catheter) group and oesp (open-ended single port catheter) group. patient controlled analgesia device will be attached to the peripheral nerve catheter of these patients. demographic data of the patients who have placed an femoral nerve catheter and used the catheter successfully for three days postoperatively, the number of pushing the button, the amount of bolus dose given and the total dose given in the patient controlled anesthesia device,the amounts of need for additional analgesia and pain scores(numeric rating scale), complications will be recorded for three days postoperatively. records will be compared statistically.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) score i-iii * upper extremity surgery exclusion criteria: * emergency surgery, * secondary surgery, * chronic pain treatment * pregnancy, * any contraindication to peripheral nerve blockade, * pre-existing peripheral nerve neuropathy, * allergy to la (study medications), * asa score ≥ 4, * neurologic or neuromuscular disease, * psychiatric disease, * renal failure, * hepatic failure, * nsaid contraindication, * inability to use a patient controlled analgesia (pca) device, * infection at the injection site * withdrawal of consent.

Keywords: femoral nerve catheter total knee arthroplasty catheter tips configurations continuous nerve block
gluten challenge in celiac disease

Conditions: Celiac Disease

Summary: up till 30 participants with celiac disease on a glutenfree diet are asked to consume gluten containing cookies or bread for 3 days. questionnaires and sampling of blood is done before, during and after.

before and 6 days after start of gluten challenge, blood samples will be collected and analysed by using hla-tetramers to identify and purify cd4+ gluten-specific t cells by flow cytometry. t cells will undergo transcriptome analysis to get an insight in signalling of antigen-specific cells. other cell populations like cd8+ t cells and γδ t cells will also be analyzed by flow cytometry.

Eligibility criteria:
inclusion criteria: * celiac disease confirmed by biopsy * age 18 - 80 years * gluten free diet last 6 months * subject has received information and signed the informed consent form exclusion criteria: * pregnant or breast feeding * probability of participant becoming pregnant (f.ex. by not using adequate sexual prevention by woman in fertile age) * drugs influencing immune system used last 3 months * current infectious disease of moderate or high severity * other chronic active intestinal disease * serious reaction on small amounts of gluten ingested

Keywords: gluten antigen-specific t cells transcriptome
study of compound edaravone injection for treatment of acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the primary objective of the study is to confirm the efficacy of compound edaravone injection via intravenous infusion every 12 hours in the patients with acute ischemic stroke(ais) in a double-blind, active-controlled manner. the study is also to examine the safety of compound edaravone injection for the ais patients.


Eligibility criteria:
inclusion criteria: * hospitalized patients, diagnosed of ischemic stroke; * onset of stroke is less than or equal to 48 hours; * there are clear signs of neurological deficit: 4≤nihss score≤24, and also, the sum of nihss score for the upper limb and the lower limb is greater than or equal to 2; * patients signed written inform consent exclusion criteria: * cranial ct scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage; * iatrogenic stroke; * severe disturbance of consciousness: nihss category 1a for consciousness is greater than 1； * the mrs score prior to this onset is greater than 1; * transient ischemic attack (tia); * sbp after blood pressure control is still greater than or equal to 220 mmhg, or dbp after blood pressure control is still greater than or equal to 120 mmhg; * patients with severe mental disorders and dementia; * alt or ast is greater than 2.0×uln or previously known liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis; * serum creatinine (scr) is greater than 1.5×uln, creatinine clearance (crcl) is less than 50 ml/min or previously known severe renal diseases; * therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, urinary kallidinogenase; * arterial or venous thrombolytic therapy has been applied after onset of stroke; * patients with malignant tumors or receiving concurrent antitumor treatment; * patients with severe systemic disease, life expectancy is less than 90 days; * allergic to edaravone , (+)-borneol or related excipients; * pregnant or lactating women; * have major surgery within 4 weeks before enrollment; * participated in other clinical studies within 30 days before randomization; or participating in other clinical trials at present; * the investigators consider the patients are not suitable for this trial.
rolandic epilepsy genomewide association international study

Conditions: Rolandic Epilepsy

Summary: we have discovered a small change in the genetic code which increases the risk of the brainwave abnormality that is found in rolandic epilepsy. we now wish to confirm this using a second much larger sample of patients. we will investigate the other genetic changes that cause people with the brainwave abnormality to develop seizures, as well as problems with speech, coordination, attention and learning.

epilepsy is a common neurological disorder affecting 1% of the population. there are over 30 types of epilepsy, some common, some rare. most epilepsies arise in childhood and have a genetic cause. approximately 25% of child patients have "rolandic epilepsy" or re, also known as benign epilepsy with centrotemporal spikes (bects). re has a complex genetic basis, probably made up of combinations of susceptibility variants in different genes. children with re quite often have other symptoms that affect their speech, attention, reading ability or coordination. the goal of this study is to find the genetic basis for susceptibility to seizures and associated comorbidities for re using genomewide association approaches. we know that re has a genetic basis and we recently discovered the genetic cause of the eeg pattern seen in re. the goal of regain is to now find the genetic basis for susceptibility to seizures and the associated symptoms above. our hope is to be able to improve diagnosis and understand why each child with re is different, and perhaps point us towards new treatments that are more effective and have fewer side effects. we will compare the genetic code of 3,000 children with re against a similar number of people not affected by epilepsy. with the proposed large sample of participants, we will be able to pinpoint the exact changes that might lead to seizures or attention problems for example. learning the genetic basis for these problems will deepen our understanding of the mechanisms and lead to new treatments or cures.

Eligibility criteria:
inclusion criteria: 1. diagnosis of rolandic epilepsy in accordance with the following international criteria: * age of first afebrile seizure 3-12 years * seizures comprising focal sensorimotor seizures affecting the vocal tract and face, with or without involvement of the arm * predominant sleep-related seizures * eeg interictal centro-temporal spikes with normal background 2. current age 6-25 years exclusion criteria: 1. no history of focal seizure 2. normal eeg or abnormal background features on eeg 3. known structural causes (stroke, tuberous sclerosis, infection, post-infectious or metabolic) 4. primary diagnosis of autism or global learning disability 5. focal central neurological deficit on clinical exam, 6. unable to provide informed consent 7. unable to provide blood sample

Keywords: epilepsy rolandic genetics genomewide association study re neurology pediatrics
study of aro-muc5ac in healthy subjects and patients with muco-obstructive lung disease

Conditions: Asthma; Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (pk) of aro-muc5ac in normal healthy volunteers (nhvs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic obstructive pulmonary disease (copd). in part 1 nhvs will receive a single dose of aro-muc5ac or placebo. in part 2 of the study, nhvs, adult patients with asthma, and adult patients with copd will receive 3 doses of aro-muc5ac or placebo.


Eligibility criteria:
inclusion criteria: * normal pulmonary function tests at screening (nhvs only) * confirmed diagnosis of asthma or copd based on source verifiable medical record (asthma and copd patients only) * no abnormal finding of clinical relevance at screening (nhvs only) * stable dose of asthma controller medications for at least 28 days prior to screening (asthma patients only) * documented treatment with an inhaled corticosteroid and at least 1 additional maintenance asthma controller medication for at least 3 months prior to screening (asthma patients only) * non-smoking (nhvs and asthma patients) * current smoker or ex-smoker with smoking history of ≥ 10 pack-years (copd patients only) * all copd treatments have been stable for at least one month prior to screening (copd patients only) * able to produce an induced sputum sample at screening * women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception. males must not donate sperm during the study and for at least 90 days following the last dose of study drug * willing to provide written informed consent and to comply with study requirements exclusion criteria: * acute lower respiratory infection within 30 days prior to first dose and/or acute upper respiratory infection within 7 days prior to first dose * positive covid-19 test during screening window * any history of chronic pulmonary disease (nhvs only) * any concomitant pulmonary disease in asthma or copd patients that could interfere with the evaluation of the study drug or interpretation of patient safety or study results * use of theophylline within 30 days prior to first dose * history of lung volume reduction surgery or pneumonectomy (copd patients) * need for chronic oxygen support at screening * clinically significant health concerns (other than asthma in asthma patients) * human immunodeficiency virus (hiv) infection, seropositive for hepatitis b virus (hbv), seropositive for hepatitis c virus (hcv) * uncontrolled hypertension * unwilling to limit alcohol consumption to within moderate limits for the duration of the study * use of illicit drugs * use of an investigational agent or device within 30 days prior to first dose note: additional inclusion/exclusion criteria may apply per protocol
towards a sex-specific "female enhanced recovery after cardiac surgery'' (f-eras) pathway:

Conditions: Female; Male; Surgery,Cardiac

Summary: the aim of this study is to evaluate the differences between men and women undergoing cardiac surgery. we will look at perioperative factors such as body weight, body surface area, previous medical history, pharmacokinetics, transfusion, coagulation, cardiopulmonary bypass (cpb) related factors, cardiac function, inotropic requirements, risk, and outcome scores as well as morbidity and mortality at 30 and 90 days, 1, 5, and 10 years.

observational, multicentre, retrospective data collection from the mandatory quality assurance database (the netherlands heart registry, (nhr), supplemented with data from the electronic patient files (epic). the retrospective data is already available. in addition, we will continue the retrospective study into a prospective registry of data after the analysis of the retrospective data. patients will be approached one, five and ten years after the operation and a questionnaire will be sent to document quality of life. no research-related interventions other than questionnaires will be performed

Eligibility criteria:
inclusion criteria: * patients \> 18 years * all patients who underwent cardiac surgery from 1 january 2016 to the start of the study, in either of the centres (amc or vumc) (retrospective) * all patients undergoing cardiac surgery from the start of the study (\~march 2022) until approximately 2032 exclusion criteria: • patients who object to the re-use of their care data or do not give consent

Keywords: anesthesia quality of life
follow-up study of patients previously treated with pimecrolimus tablets for atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.


Eligibility criteria:
inclusion criteria: * consenting patients who participated in the core clinical trial

Keywords: safety, atopic dermatitis, adverse event, sae, extension
efficacy and safety of single-port surgical robot system in thoraic surgery

Conditions: Lung Cancer

Summary: robotic surgical systems have become a promising surgical assistance system, with unique advantages such as 3d high-definition visual system, highly flexible wrist-jointed instruments, and automatic fitering of hand tremors. robotic surgical systems is applied in various fields including urology, general surgery, cardiothoracic surgery, head and neck surgery, and gynecology. currently, the da vinci surgical robot system is the most widely used robot system globally. however, the da vinci robot system for single-port laparoscopic surgery has not yet been launched in china. therefore, the investigators conduct a prespective, single-center study to evaluate the efficacy and safety of single-port surgical robot system in thoracic surgery.


Eligibility criteria:
inclusion criteria: * age between 18 and 75 years, regardless of gender. * patients who require endoscopic surgical treatment and have indications for lung segment/lobe resection; for pre-trial subjects, there is no restriction on the type of procedure, and inclusion is based on the investigator's judgment of having indications for thoracic surgery. * preoperative asa classification of i-iii. * voluntary participation in the clinical trial and willingness to provide informed. consent, either by the subject or their guardian. * willingness to cooperate and complete trial follow-up and related examinations. exclusion criteria: * patients with a history of thoracic surgery or previous history of other malignant tumors deemed unsuitable for inclusion by the investigator. * patients with severe comorbidities (cardiac, pulmonary, hepatic, cerebral, renal diseases) or physical weakness who cannot tolerate general anesthesia or surgery. * patients with severe bleeding tendencies or coagulation disorders. * patients in the active phase of infectious diseases or with other severe non-communicable infections. * patients positive for human immunodeficiency virus (hiv) antibodies or syphilis seropositive patients. * patients with a suspected or confirmed alcohol, drug, or substance addiction. * patients with a history of epilepsy, mental illness, or cognitive impairment. * women who are pregnant, breastfeeding, or planning to become pregnant during the trial period. * participation in other interventional clinical trials within 3 months prior to signing the informed consent form. * other situations in which the investigator deems inappropriate for participation in this clinical trial.

Keywords: surgical robot system efficacy safety thoracic surgery
sildenafil for post-capillary pulmonary hypertension in patients undergoing cardiac surgery

Conditions: Pulmonary Hypertension

Summary: pulmonary hypertension increases the perioperative risk in patients undergoing cardiac surgery for valvular heart diseases, especially in patients with a long life mitral valve disease. the present study wants to test the hypothesis that intravenous administration of sildenafil reduces pulmonary vascular resistances and afterload of the right ventricle.

pulmonary hypertension represents an increased risk for perioperative patients undergoing cardiac surgery for valvular heart disease especially in patients with a long life mitral valve disease complicated by sever pulmonary hypertension, with high risk of developing post operative right ventricular failure during separation from cardiopulmonary by pass. a recent study showed that a single oral administration of sildenafil at the beginning of the cardiac intervention in patients undergoing valvular heart surgery complicated by pulmonary hypertension reduces pulmonary vascular resistances without inducing significant effects on systemic vascular resistances. the present study wants to test the hypothesis that intravenous administration of sildenafil reduces pulmonary vascular resistances and afterload of the right ventricle avoiding right ventricular failure. this should support weaning from cardiopulmonary by pass in patients undergoing cardiac surgery for valvular heart diseases associated to pulmonary hypertension.

Eligibility criteria:
inclusion criteria: * all patients undergoing valvular heart surgery associated to post capillary pulmonary hypertension with a mean pulmonary arterial pressure (mpap)\>30mmhg or pulmonary vascular resistance (pvr)\>3wu. exclusion criteria: * patients younger than 18 years old * ischemic cardiomyopathy * ejection fraction (ef)\<30% * severe chronic obstructive pulmonary disease (copd) with oxygen and bronchodilators therapy * chronic pulmonary disease, chronic renal failure on dialysis * hepatic failure * patients with orotracheal intubation and already admitted to the icu before the intervention